Drug manufacturers Xellia Pharmaceuticals and Chartwell Rx have notified 340B covered entities about possible refunds for overcharges.
Xellia notified 340B covered entities about refunds for overcharges on 16 NDCs for its antibiotics vancomycin, daptomycin, and colistimethate.
Xellia posted the public notice last week on the U.S. Health Resources and Services Administration (HRSA) website. The refunds are for purchases from Q4 2018 through Q1 2020. The company said it was providing refunds through its agent ICS Amerisource Bergen Specialty Group if company data showed entities overpaid for the products. “All credits should be issued to wholesalers by May 31, 2021,” the notice says. It asks entities to direct all questions to Barbara.firstname.lastname@example.org.
Xellia is owned by Novo Holdings, Danish drug manufacturer Novo Nordisk’s holding company. It makes vancomycin, daptomycin, and other antibiotics for the health system-owned nonprofit generic drug company Civica Rx and was Civica’s first supplier partner. Civica in April separately published its own public notice about refunds for overcharges on several different 340B covered outpatient drugs.
New York-based generic drug manufacturer Chartwell Rx last week posted a notice on HRSA’s website about possible refunds for overcharges on unspecified drugs bought between Oct. 1, 2020 and Jan. 31, 2021.
Chartwell said it “has identified all covered entities that may be owed a refund for purchases during this timeframe and is in the process of directly contacting any covered entity owed a refund greater than $10.00 by U.S. mail.” It said “refund checks will be issued to the facility and matching Federal Tax ID number.” It asked entities to direct their questions to email@example.com by June 1, 2022.